These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Author: Baumann BC, Baumann JC, Christodouleas JP, Soffen E.
    Journal: Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422.
    Abstract:
    PURPOSE: Local recurrence (LR) of prostate cancer after external beam radiotherapy (EBRT) is a serious problem. Our purpose was to determine if reduced-dose salvage brachytherapy could achieve high rates of biochemical control with acceptable toxicity if combined with androgen deprivation therapy (ADT). METHODS AND MATERIALS: Thirty-three consecutive patients with LR after EBRT were treated with salvage brachytherapy plus ADT from 1998 to 2013. All had pathologically confirmed LR, disease-free interval ≥18 months after EBRT, no distant/nodal metastasis, and International Prostate Symptom Score ≤15. Whole-gland salvage treatment was delivered using low-dose-rate (median 100 Gy with 103Pd, n = 25) or high-dose-rate brachytherapy (30 Gy in 6 fractions over 4 weeks, n = 8) plus 4-6 months of neoadjuvant plus adjuvant ADT. RESULTS: Fifty-five percent had high-risk disease at diagnosis. Median EBRT dose was 70.2 Gy; median prostate-specific antigen nadir was 0.8 ng/mL. Median time to recurrence was 56 months; median presalvage prostate-specific antigen was 5.0 ng/mL. Median postbrachytherapy followup was 61 months (range 7-150 months). Five and 7-year relapse-free survival, distant metastasis-free survival, and overall survival were 79% and 67%; 93% and 86%; and 94% and 85%, respectively. Freedom from late Grade 3 GU toxicity at 5 years was 85%. There were no late Grade ≥2 GI toxicities. CONCLUSIONS: This is the largest series of salvage brachytherapy combined with neoadjuvant plus adjuvant ADT and uses reduced-dose brachytherapy. Results suggest that reduced-dose salvage brachytherapy is feasible and reasonably well tolerated when combined with ADT. Compared to prior series, this approach was associated with favorable relapse-free survival. Prospective studies of reduced-dose salvage brachytherapy plus ADT are warranted.
    [Abstract] [Full Text] [Related] [New Search]